Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Is Swartz Schedule 13G Due According To Rule 13d-1(c) NLT Feb 14?

From SB-2/A OCTOBER 1, 1999:

"SHAREHOLDER APPROVAL. We may issue more than 20% of our outstanding shares." 

 

From S-1 (08/28/02):

"Key Facts

     
Shares being offered for resale to the public   22,363,391 (27.5% of our shares currently outstanding)

   
Total shares outstanding prior to the offering   81,465,757 as of August 12, 2002

   
Total shares outstanding after the offering   103,829,148

   
Total shares that would be outstanding assuming full conversion of the current offering and exercise of all outstanding options and warrants
  144,543,700

""During fiscal 2002, the Company issued warrants to purchase 23,197,201 common shares of stock at exercise prices ranging from $0.048 to $0.54 per share...."

 

"

Lincoln Ventures, LLC
    27,910,526 (2)     17,720,864       10,189,662 (2)     10.27 %(2)"

 

If you follow through ALL the filings from 99 to 2005 you'll see not only the staedy increase of the OS caused by the warrants & shares, but also that Swartz (and Lincoln, which came up as "a group of six investors" via a private placement in April 2002) owned a lot more than the 10% of the company. BTW, if you look at the filings in 2001 and 2002 there is NO doubt for me, that SPE and LV owned each own more than 10% (see above)

Or maybe I mis-translate the filings...? 

GLTY

 

Share
New Message
Please login to post a reply